-

02:20:51 AM

MDWD Stock News

MDWD - MediWound Ltd

12/29/22 1:46 PM

Nasdaq : MDWD

fda approvallow float

MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second quarter of 2023 YAVNE,

RHEA-AI

very positive

12/23/22 8:00 AM

Nasdaq : MDWD

low float

MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan

MediWound Ltd. (Nasdaq: MDWD), a fully integrated

RHEA-AI

very positive

12/20/22 8:00 AM

Nasdaq : MDWD

low float

MediWound Strengthens European Presence of NexoBrid®

MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation

RHEA-AI

very positive

12/19/22 7:00 AM

Nasdaq : MDWD

low float

MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company, focused

RHEA-AI

positive

12/13/22 5:30 AM

Nasdaq : MDWD

low float

MediWound Expands Global Presence as NexoBrid® Gains Approval in India

MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation

RHEA-AI

neutral

12/05/22 4:05 PM

Nasdaq : MDWD

low float

MediWound Announces a 1-for-7 Reverse Share Split

MediWound Ltd. (Nasdaq: MDWD) (“ MediWound ” or the “ Company ”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it intends to effect a

RHEA-AI

positive

11/15/22 7:00 AM

Nasdaq : MDWD

earningslow float

MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update

$30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company f ocus ed on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in first-half

RHEA-AI

neutral

11/09/22 8:00 AM

Nasdaq : MDWD

low float

MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs

MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation

RHEA-AI

neutral

11/03/22 8:00 AM

Nasdaq : MDWD

conferencesearningslow float

MediWound to Report Third Quarter 2022 Financial Results

MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and

RHEA-AI

neutral

10/25/22 7:00 AM

Nasdaq : MDWD

managementlow float

MediWound Announces Formation of Strategic Advisory Board

MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next